Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Nektar Therapeutics ( (NKTR) ).
On September 18, 2025, Nektar Therapeutics announced new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, a potential first-in-class therapy for atopic dermatitis. The study’s results highlight rezpegaldesleukin’s efficacy in restoring immune balance by inducing regulatory T cells, offering potential long-term control for patients with moderate-to-severe atopic dermatitis who have not responded to traditional therapies.
The most recent analyst rating on (NKTR) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics’ overall stock score is primarily impacted by its weak financial performance, which poses significant risks. However, positive earnings call sentiment and corporate events provide some optimism, supported by strong technical indicators suggesting bullish momentum. Valuation concerns remain due to ongoing financial losses.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics operates in the biopharmaceutical industry, focusing on the development of novel therapies for chronic diseases. The company specializes in creating drugs that modulate the immune system, with a particular emphasis on treatments for autoimmune diseases and cancer.
Average Trading Volume: 2,213,088
Technical Sentiment Signal: Hold
Current Market Cap: $971.3M
For an in-depth examination of NKTR stock, go to TipRanks’ Overview page.